Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 65273
IPSCIO Record ID: 28771
A second patent (patent number 5,391,547), dealing with treatment of cancers of the lung, was Licensed on February 21, 1995, and the patent expires on February 21, 2012.
The third Licensed patent (patent number 6,490,330) for the production of high specific activity Copper 67, was Licensed on December 3, 2002, and the patent expires on December 3, 2019.
The patents in these countries protect our rights under U.S. The following is a summary of the important terms and conditions of the License Agreement. Rights of obtained We have obtained from the University of California, a worldwide, exclusive License for the commercial development, manufacture, use, and subLicense of the technology and to practice Licensed method for the life of the patent.
The Licensee also has the right to subLicense our rights to the Licensed patents.
Technology means technical information, know-how and data owned or controlled by the Licensor and relating to the early detection and treatment of lung cancer using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin and contained in the University's rights arising from the following a) U.S. Patent No. 5,162,231; Method Using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin for Detecting Cancers of the Lung; b) U.S. Patent No. 5,391,547; Method Using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphyrin for Treating Cancers of the Lung; c) U.S. Patent No. 6,490,330; Production of High Specific Activity Copper -67.
The Licensee must use best efforts to fully exploit the Licensed patent's business and market potential and to reach established milestones.
The License Agreement had certain diligence milestones that were required to be reached, including the development of the first working diagnostic test kit by January 1, 1998 and our first commercial sale by September 20, 1998. The Licensee satisfied both of these milestones before their deadline.
IPSCIO Record ID: 260378
MatemiT21 PLUS Test shall mean the laboratory-developed test for the non-invasive testing of a plasma sample from a pregnant woman for the detection and diagnosis of prenatal aneuploidy and/or fetal abnormalities by use of cell-free fetal nucleic acids, currently known as the MatemiT21 PLUS test, as performed by Licensors Laboratories.
The MaterniTÂ® 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta. It analyzes the amount of chromosome 21 in fetal DNA picked up from the maternal blood sample. It can detect an increased amount of chromosome 21 material which is associated with trisomy 21 (Down syndrome). It is completely non-invasive as it only involves a blood sample from the mother.